Back HIV/AIDS

HIV / AIDS

IDWeek 2015: Emergency Needle Exchange Reduces HIV and HCV Risk in Indiana

An emergency syringe exchange program implemented after an outbreak of HIV earlier this year in Indiana led to a decrease in risk behaviors including needle sharing over its first 5 months, researchers reported at IDWeek 2015 last week in San Diego. These findings add to the evidence that needle exchange is an effective harm reduction intervention for people who inject drugs.

alt

October 15 is National Latino AIDS Awareness Day; CDC Finds Rise in HIV Among Latino Gay Men

October 15 is National Latino AIDS Awareness Day(NLAAD), an opportunity to call attention to the continued threat HIV poses to Latino and Hispanic people in the U.S. According to a new report from the Centers for Disease Control and Prevention (CDC), while the overall rate of HIV infection among Latinos has dropped in recent years, there has been a sharp increase among Latino gay and bisexual men. 

alt

U.S. Physicians Routinely Offer Early HIV Treatment, But Only a Third Have Prescribed PrEP

Most doctors at the frontline of the HIV epidemic in the United States recommend early antiretroviral therapy (ART) and many also believe they have a role in providing pre-exposure prophylaxis (PrEP) to the uninfected partners of their patients living with HIV, according to research published in the online edition of Clinical Infectious Diseases. Overall, 87% of doctors recommended ART from the point of diagnosis and most thought PrEP was appropriate in some circumstances. However, only a third had actually prescribed PrEP.

alt

IDWeek 2015: Studies Continue to Support Tenofovir Alafenamide as it Nears Approval

A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression when switching from other combinations and was associated with improved kidney function and bone health, according to studies presented at IDWeek 2105 last week in San Diego. Other research showed that the new formulation works better than the old one for black patients and for older people, and that it can be safely used with sofosbuvir/ledipasvir (Harvoni) for hepatitis C treatment.

alt

IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study

Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.

alt

IAPAC Summit: At Least 25,000 People in the U.S. May Now Be Using PrEP

As many as 30,000 people in the U.S. may now be taking pre-exposure prophylaxis (PrEP) to prevent HIV, researchers reported at the 4th IAPAC Controlling the HIV Epidemic with Antiretrovirals summit in Paris last week. Meanwhile, as the summit also heard, European and other countries face frustrating delays in securing access to PrEP.

alt

ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients

Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.

alt